Evoclin patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7374747 MYLAN Pharmaceutical foam
Jan, 2024

(3 months from now)

US7141237 MYLAN Pharmaceutical foam
Feb, 2024

(4 months from now)

Evoclin is owned by Mylan.

Evoclin contains Clindamycin Phosphate.

Evoclin has a total of 2 drug patents out of which 0 drug patents have expired.

Evoclin was authorised for market use on 22 October, 2004.

Evoclin is available in aerosol, foam;topical dosage forms.

Evoclin can be used as treatment of acne vulgaris.

The generics of Evoclin are possible to be released after 03 February, 2024.

Drugs and Companies using CLINDAMYCIN PHOSPHATE ingredient

Market Authorisation Date: 22 October, 2004

Treatment: Treatment of acne vulgaris


How can I launch a generic of EVOCLIN before it's drug patent expiration?
More Information on Dosage

EVOCLIN family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic